Scalp Cooling for Alopecia

This trial examines how the PAXMAN Scalp Cooling System might help breast cancer patients undergoing chemotherapy retain their hair and improve their quality of life. The researchers aim to determine if cooling the scalp can reduce hair loss and promote regrowth. Participants will have their hair condition photographed to track changes and assess the role of genetic factors. Suitable candidates have stage I to III breast cancer and are receiving specific chemotherapy treatments known to cause hair loss. As an unphased trial, this study offers a unique opportunity to contribute to research that could enhance the quality of life for future patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Paxman Scalp Cooling System is generally safe for reducing hair loss caused by chemotherapy. In a study of nearly 2,000 patients, only 0.61% experienced cancer spread to the scalp over an average of about 43 months. This low rate suggests the treatment is well-tolerated.

The system effectively preserves hair during chemotherapy, with 53 out of 95 patients successfully keeping their hair. The device is FDA-cleared, indicating it has been reviewed and approved for safety for certain uses.

Researchers are excited about the Paxman Scalp Cooling System because it offers a unique approach to managing chemotherapy-induced alopecia (CIA). Unlike traditional methods that mainly involve wigs or topical applications, this system works by cooling the scalp to reduce blood flow to hair follicles during chemotherapy, thereby minimizing hair loss. This non-invasive method not only aims to preserve the patient's natural hair but also enhances their quality of life by addressing the emotional and psychological impacts of hair loss during cancer treatment.

Research has shown that the Paxman Scalp Cooling System can help reduce hair loss caused by chemotherapy in breast cancer patients. In this trial, participants in the treatment arm will use the Paxman Scalp Cooling System, while those in the control arm will not receive any hair retention treatment. One study found that 43% of patients using scalp cooling retained enough hair to avoid wearing head coverings by the end of their treatment. Another study reported that 56% of patients didn't need a head covering during their last chemotherapy session, and 53% experienced only minimal hair loss. Overall, several clinical trials have consistently shown that scalp cooling lessens hair loss.¹²³⁶⁷